Edward A. Faber Jr., D.O., M.S.

Find a Doctor

Physician Profile

Edward A. Faber Jr., D.O., MS

“Cancer is a complex journey made easier by family and friends, the application of newer therapies derived from proven research and experience. I want to believe that I travel this journey hand-in-hand with my patients, doing my best to support their unique medical and personal needs every step of the way.”
Learn More.

Practices

Blood & Marrow Transplants
Hematology
Medical Oncology

Locations

Kenwood

Request
appointment

or call
1-800-710-4674

Edward A. Faber Jr., D.O., MS

Upon graduation from Allegheny College, Dr. Faber pursued research in the Pharmacology Department at the University of Pittsburgh, and then completed a Master’s of Science degree in Genetics from Duquesne University while supervising the Molecular Diagnostics Lab at the Western Pennsylvania Cancer Institute.

After graduating from Lake Erie College of Osteopathic Medicine (LECOM), he completed a dual osteopathic and allopathic internship at University of Pittsburgh Medical Center (UPMC) – Mercy Hospital. He then continued his training at UPMC – Mercy Hospital to complete an Internal Medicine residency. Finally, he completed his clinical education with a fellowship in Hematology/Oncology at Michigan State University. Dr. Faber is board certified through the American Board of Internal Medicine (ABIM) in Internal Medicine, Hematology, and Medical Oncology.

Dr. Faber was an assistant professor of medicine at the University of Nebraska Medical Center (UNMC) for the past four years. He treated malignant hematology (blood cancers), benign hematology (bleeding and clotting disorders) and bone marrow transplantation patients. For example, acute leukemias, chronic leukemias, Hodgkin’s and non-Hodgkin’s lymphomas, myeloma, myelodysplastic syndromes, aplastic anemia, polycythemia vera, essential thrombocythemia, myelofribrosis, amyloidosis, and acquired/inherited clotting or bleeding disorders. Dr. Faber is also highly experienced in autologous and allogeneic bone marrow transplantation.

While at UNMC, Dr. Faber directed a comprehensive, multidisciplinary program for multiple myeloma, which was accepted as a Center of Excellence for the care of multiple myeloma patients. He was the principal investigator for new diagnosed, relapsed/refractorym and transplant-related clinical trials, in addition to serving as a multiple myeloma and Waldenstrom’s macroglobulinemia panel member for the National Comprehensive Cancer Network (NCCN). He currently participates as a member of the Myeloma and Transplant Committees for the Alliance for Clinical Trials in Oncology, the Plasma Cell Disorders Working Committee of CIBMTR, and the Myeloma Committee for the BMT CTN. Dr. Faber also serves as the national physician advisor for the education project of the Association of Community Cancer Centers (ACCC): Improving Quality Care for Multiple Myeloma and has been appointed as an advisory panelist for amyloidosis on ASCO’s Cancer.Net Editorial Board.

Dr. Faber was also the director of UNMC’s Hematology/Oncology Course and participated on the Hematology/Oncology Fellowship Committee. He continues to collaborate with basic science researchers at UNMC and the University of North Carolina to develop a new therapy which can overcome drug resistance in relapsed/refractory myeloma patients.

Among his many awards, he was nominated as the “Man of the Year” by the Leukemia Lymphoma Society in 2013 and was also named “Resident of the Year” in the final year of his internal medicine residency. On a personal note, Dr. Faber’s interests include biking, golfing, hockey, and aspirations to become a professional chef.

SPECIALTIES

Malignant hematology (blood cancers): acute leukemias, chronic leukemias, Hodgkin’s and non-Hodgkin’s lymphomas, myeloma, myelodysplastic syndromes, aplastic anemia

Benign hematology (non blood cancers): polycythemia vera, essential thrombocythemia, myelofribrosis, amyloidosis and acquired or inherited clotting and bleeding disorders

Blood and marrow transplantation: autologous and allogeneic bone marrow and peripheral blood stem cell transplants

MEDICAL INTERESTS

Bone and marrow transplants (BMT)
Cancer clinical trials and research

PERSONAL INTERESTS

Biking, golfing, hockey, and aspirations to become a professional chef.

MEDICAL SCHOOL

Lake Erie College of Osteopathic Medicine, Erie, PA

INTERNSHIP

University of Pittsburgh Medical Center (UPMC) – Mercy Hospital

RESIDENCY

University of Pittsburgh Medical Center (UPMC) – Mercy Hospital

FELLOWSHIP

Michigan State University, Hematology/Oncology

ADDITIONAL EDUCATION

Penn State University, Behrend College, Certificate in Healthcare Management, Erie, PA
Duquesne University, Pittsburgh, Master of Science in Genetics and Molecular Biology
Allegheny College, Meadville, PA, BS in Biology and Chemistry

CERTIFICATIONS & LICENSURES

American Board of Internal Medicine, Internal Medicine
American Board of Internal Medicine, Medical Oncology
American Board of Internal Medicine, Hematology

MEMBERSHIPS

American College of Physicians
American Medical Association
American Society of Hematology
American Society of Bone Marrow Transplant

AWARDS & HONORS

ASBMT Clinical Research Training Course, July 2009 CSCR/MWAFMR Midwest Trainee Travel Award, April 2009 Managing Myeloma Scholarship, February 2009 First Place, ACP Scientific Meeting Abstract Presentation, “Positive Axillary Lymph Node and BRCA Gene Mutation in DCIS,” September 2007 Resident of the Year, University of Pittsburgh-Mercy Hospital, May 2006

PUBLICATIONS

Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber Jr EA, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockert-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F. Multiple Myeloma. J Natl Compr Canc Netw. 2011 Oct;9(10):146-83. PMID 21975914.

Faber Jr EA, Vose JM. The Role of Hematopoietic Cell Transplantation in Follicular Lymphoma. J Natl Compr Canc Netw. 2010 Mar;8(3):337-45. PMID: 20202463.

Faber Jr EA, Geyer S. Vena Cava Thrombosis and Fatal Pulmonary Death. Lab Medicine 33:553-555, 2002.

Andrews III DF, Faber E, Hawk H, Geyer S. Antisense Oligonucleotides to MDR1 Increase Adriamycin Susceptibility in Breast Cancer Cell Lines. Molecular Biology of Hematopoiesis. Ed. N.G. Abraham, et al. Plenum Press, NY, NY, 1996.

ABSTRACTS AND POSTERS

William BM, Raichlin Em Um JY, Morris MC, Miles CD, Gorggel GC, Faber Jr EA. Successful autologous stem cell transplant (ASCT) following a combined heart-kidney transplantation for AL amyloidosis. Poster. BMT Tandem Conference, February 2012.

Raje NS, Hohl RJ, Faber EA, Richardson PGG, Forero-Torres A, Schiller GJ, Cohen AD, Carpenter SP, Cronier D, Pashkevich M, Wooldridge J, Anderson KC. Phase 1 study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously-treated multiple myeloma. J Clin Oncol (ASCO Annual Meeting Abstracts) 29: Suppl Abstr 8012. 2011.

Martin K, Reade C, Faber Jr EA. "Acute Severe Hypophosphatemia in IgG kappa Multiple Myeloma Treated with Lenalidomide". American College of Physicians, Nebraska Chapter Meeting. 2009.

Faber Jr EA, KA Schwartz, S Nagpal, et al. Hypercoagulation in Malignancy: Localized by Thromboelastography [TEG] to the Humoral Phase of Coagulation. CSCR/MWAFMR Chicago, IL 2009, Poster Number 75 and ISTH, Boston MA, Poster PP-WE-495. 2009.

S Nagpal, KA Schwartz, Faber Jr EA, et al. The Role of Thromboelastography (TEG) in Predicting Thrombosis in Cancer Patients. Blood (ASH Annual Meeting Abstracts) 112: Abstract 5352, 2008.

Faber Jr EA, Alirah S, Tamkus D. Case Report: DCIS and BRCA, the Value of Sentinel Lymph Node Biopsy. ACP Scientific Meeting. September 2007.

Faber E, Andrews DF, Shadduck RK, Geyer S, Agha ME. Improved Efficiency of Growth Inhibition of BCR-ABL Positive Cells by Antisense Oligodeoxynucleotides - Cholesterol. ASH Conference. December 1995.

Andrews III DF, Geyer S, Hawk S, Faber E. Antisense Oligonucleotides to MDR1 Increase Adriamycin Susceptibility in Breast Cancer Cell Lines. 17th Annual San Antonio Breast Cancer Symposium. December 1994.

Like all OHC physicians, Dr. Faber has full access to the OHC clinical trial research program.

We encourage our patients to discuss all of their healthcare options — including Clinical Trial research programs — with their doctor.

The following are recent reviews provided by actual OHC patients:

"Dr. Faber is very knowledgeable and helpful with my disease."

"Dr. Faber has been wonderful!"

"He is very helpful and willing to answer any and all questions I have."

OHC

Find a Doctor

Physician Profile